Eastman Kodak’s potentially lucrative deal to help the U.S. government make more generic drugs domestically is threatening to turn into a regulatory headache for the fallen photography giant.
Kodak’s depressed stock price surged last week before the company announced its plans to work with the President Donald Trump’s administration in exchange for a $765 million loan. That prompted Sen. Elizabeth Warren to send a Monday letter asking the Securities and Exchange Commission to investigate whether insider trading laws have been broken.
The SEC is now in the early stages of a probe, according to a report published Tuesday by The Wall Street Journal. The newspaper cited unidentified people familiar with the matter.
The SEC declined to comment on the report.
Kodak said Tuesday that the Rochester, New York, company intends to cooperate with any potential inquiries, without saying whether it has been contacted by the SEC.
The company’s stock soared